Europe’s lessons for the U.S. on how to cover weight loss drugs; In mifepristone case, the Supreme Court must affirm the FDA’s authority. Medical innovation is at risk

Taking stock of the drug industry, from the lab to the medicine chest

December 14, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: Europe's lessons for the U.S. on how to cover weight loss drugs Reimbursement policies in Norway, the Netherlands, Poland, and Italy offer a possible path to affordable weight loss drug coverage in the U.S. By George Hampton Opinion: In mifepristone case, the Supreme Court must affirm the FDA's authority. Medical innovation is at risk Allowing judges to intervene on drug safety is not only scientifically inappropriate; it also poses a serious threat to medical innovation. By Eva Temkin and Grace Colón STAT+ | Jay Bradner, former Novartis research leader, to head up Amgen's scientific efforts Bradner is taking over for Amgen veteran David Reese, who is becoming the company's chief technology officer. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser